found (fixed and random-effects model I 2 was 4%). However for this outcome measure, the overall estimate of effect and degree of statistical heterogeneity were sensitive to the model used for meta-analysis. Progression of illness, defined by requirement for further antibiotics, was significantly lower in the treatment group (OR 0.10, 95%CI 0.03 to 0.34), NNT was 4 (95% CI 3 to 5). Adverse events were not significantly increased in the treatment group.
Authors' conclusions
Antibiotics are likely to be beneficial in the treatment of children with chronic moist cough. This evidence is however limited by study quality, study design and sensitivity analysis data. The use of antibiotics however has to be balanced against their well known adverse events. Further well-designed RCTs using valid cough outcome measures are needed to answer this question conclusively.
P L A I N L A N G U A G E S U M M A R Y

Antibiotics for prolonged moist cough in children
Cough is the most common symptom which presents to doctors. Some people recommend treating prolonged moist cough with antibiotics. Two small RCTs were available for analysis although both have methodological flaws. They found that treatment with antibiotics for prolonged moist cough in children was beneficial with one clinical cure for every three children treated. Antibiotics resulted in the prevention of illness progression for one in every four patients treated. There were no significant side effects in these trials. Long-term outcomes were not assessed. This evidence is limited by poor study design and quality. This review supports the use of antibiotics in children with prolonged wet cough. However further RCTs using better study design, specifically the inclusion and exclusion factors and validated outcome measures, are required.
B A C K G R O U N D
Cough is the most common symptom which presents to doctors (Britt 2004) . The magnitude of the problem is illustrated by the amount spent globally on over the counter medications for cough. In the United Kingdom £92.5 million is spent yearly on cough syrup. In the United States several billion dollars are spent yearly on cough and cold pharmaceuticals (Morice 2002). A US survey showed that 35% of preschool-aged children had used overthe-counter medications for cough in the previous month (Kogan 1994) . A study of primary school aged children described a lifetime prevalence of bronchitis of 55.9% (Leonardi 2002) . The prevalence of chronic cough reported in a large European study was 3% of school-aged children and 9% in the preschool age group. The problem was more common in the lower socioeconomic groups (Spee-van 1998). However, the lack of reliable reporting of cough limits interpretation of such data (Chang 2001).
The definition of chronic cough in children varies from three to eight weeks (Chang 2001). As cough due to an acute upper respiratory tract infection (URTI) is predominantly limited to one to three weeks duration (Hay 2002) , it is arguably logical to define chronic cough as cough lasting over three weeks. A review of the natural history of acute cough found that 5-10% of preschool aged children still cough at three weeks and these children have 'complicated' upper respiratory tract infections (Hay 2002) . In this review, prolonged cough is defined as cough lasting longer than 10 days.
Wet/moist and dry cough can be clinically well differentiated by clinicians and parents (Chang 2005) . A dry cough in the absence of identifiable respiratory disease (i.e. absence of other symptoms and signs) or known aetiology is also termed non-specific cough (Chang 2003) . Children with non-specific cough do not have any of the pointers associated with specific cough (Chang 2001) . Chronic cough that is moist-sounding or productive is referred to as specific cough because the increased production of airway secretions reflects a degree of primary pulmonary pathology.
The role of antibiotics in chronic or prolonged cough is unclear. Antibiotics provide a modest benefit in the treatment of acute bronchitis (Fahey 2004 ) and have no efficacy in treatment of the common cold (Arroll 2005) . In children with prolonged cough, the American Pediatric URI Consensus Team surmised that "antimicrobial treatment for prolonged cough (longer than 10 days) may be indicated occasionally" (Dowell 1998). Despite these conservative recommendations, antibiotics are often prescribed. Questions concerning the benefits and harm of antibiotic treatment in these circumstances need to be resolved.
O B J E C T I V E S
To determine the efficacy of antibiotics in treating children with prolonged moist cough (excluding children with bronchiectasis or other underlying respiratory illness).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing antibiotics with a placebo medication or 'no treatment' control group.
Types of participants
All trials which included children under 18 years of age with prolonged moist cough (longer than 10 days). A priori subgroup analyses were planned for children under seven years of age and cough lasting over three weeks). Exclusion criteria: radiological evidence of bronchiectasis or lung histopathological evidence of bronchiectasis, diagnosis of cystic fibrosis, cough related to Mycoplasma pneumoniae, B.pertussis and Chlamydia, presence of underlying cardiorespiratory condition (haemoptysis, recurrent pneumonia, chronic dyspnoea), current or recurrent wheeze (over two episodes), presence of the respiratory signs of clubbing or wheeze on auscultation, presence of any sign of systemic illness (failure to thrive, aspiration, neurological or developmental abnormality and immune deficiencies).
Types of interventions
All randomised controlled comparisons of antibiotics versus placebo or control group in the management of prolonged moist cough. Antibiotics could be given via any route. Trials only comparing two or more antibiotics without a placebo were not included. It was planned that three separate treatment regimes would be evaluated: i) Short term treatment (seven days or less) ii) Long term antibiotics (more than seven days) iii) Intravenous antibiotic treatment where antibiotics were given intravenously for at least five days Trials that included the use of other medications or interventions were included if all participants had equal access to such medications or interventions or if the additional therapies were regarded as ineffective.
Types of outcome measures
Attempts were made to obtain data on at least one of the following outcome measures:
Primary outcomes
Proportions of participants who were not cured or not substantially improved at follow up (clinical failure). The proportions of participants who failed to improve on treatment and the mean clinical improvement were determined using the following hierarchy of assessment measures (i.e. where two or more assessment measures were reported in the same study, the outcome measure that is listed first in the hierarchy was used). i) Objective measurements of cough indices (cough frequency, cough receptor sensitivity, cough amplitude). ii) Symptomatic (Likert scale, visual analogue scale, level of interference of cough, cough diary, sputum production -quantity and colour, general well-being) -assessed by the child. iii) Symptomatic (Likert scale, visual analogue scale, level of interference of cough, cough diary, sputum production -quantity and colour, general well-being) -assessed by the parents/carers. iv) Symptomatic (Likert scale, visual analogue scale, level of interference of cough, cough diary, sputum production -quantity and colour, general well-being) -assessed by clinicians. v) Airway markers (sputum or BAL) consistent with infection or inflammation. vi) Sputum volume alone. vii) Lung function tests alone.
Secondary outcomes
a) Mean difference in symptoms (mean improvement in clinical state); b) Mean difference in sputum, bronchoalveolar lavage (BAL) or blood indices of inflammation or infection (mean improvement in markers of infection); c) Mean difference in cough indices (cough diary, cough frequency, cough scores), d) Proportions of participants with progression of the disease resulting in additional medical therapy (complications); e) Proportions experiencing adverse effects of antibiotics e.g. diarrhoea, nausea, skin rash, allergic reactions (side effects). For studies where data was not available on any of the pre-specified outcome measures but the study was eligible for inclusion it was planned to described the outcome measures in the 'Characteristics of the included studies' table. However these studies would not have been included in the meta-analyses.
Search methods for identification of studies
The following topic search strategy was used to identify relevant randomised controlled trials. 
Data collection and analysis
Retrieval of studies: From the title, abstract, or descriptors, two reviewers (JM, JG) independently reviewed literature searches and identified potentially relevant trials for full review. Searches of bibliographies and texts were also conducted to identify additional studies. Using specific criteria, the same two reviewers independently selected trials for inclusion in the review. It was planned that disagreement would be resolved by third party adjudication (AC). Trials that satisfied the inclusion criteria were reviewed independently by two reviewers (JM, AC). The following information was recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible children), inclusion and exclusion criteria, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of antibiotic therapy, duration of therapy, cointerventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intentionto-treat analyses were possible. Data were extracted on the outcomes described previously by two reviewers (JM, AC) and double entry of data for meta-analysis was used. Further information was requested from the authors of both studies.
1. Studies included in the review were independently assessed for quality by two reviewers. Four components of quality were assessed: 4. Reporting of participants by allocated group. Trials were scored as: Grade A: The progress of all randomised children in each group described, Grade B: Unclear or no mention of withdrawals or dropouts, Grade C: The progress of all randomised children in each group clearly not described. (Grade A = high quality).
5. Follow-up. Trials were scored as: Grade A: Outcomes measured in >90% (where withdrawals due to complications and side-effects are categorised as treatment failures), Grade B: Outcomes measured in 80-90%, Grade C: Unclear, Grade D: Outcomes measured in <80%. (Grade A = high quality). While only the allocation concealment quality assessment are displayed in the meta-analysis figures, all assessments have been included in the 'Characteristics of included studies' table. Inter-reviewer reliability for the identification of high quality studies for each component was measured by the Kappa statistic. Each study was also assessed using a 5-point scale described by Jadad et al (Jadad 1996) and summarised as follows: Was the study described as randomised? (1=yes; 0=no) Was the study described as double blind? (1=yes; 0=no) Was there a description of withdrawals and dropouts? (1=yes; 0= no) Was the method of randomisation clearly described and appropriate? (1=yes; 0=no) Was the method of double blinding well described and appropriate? (1=yes; 0=no) Statistics For the dichotomous outcome variables of each individual study, odds ratios were calculated using a modified intention to treat analysis. This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies examined whether pooling of results (meta-analysis) was reasonable. This took into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size. The results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the subsequent meta-analyses. The summary weighted odds ratio and 95% confidence interval (fixed-effects model) were calculated using the inverse of the variance of each study result for weighting (Cochrane statistical package, RevMan 4.2). Number needed to treat (NNT) was calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003) . This calculator converts the risk in the placebo group to the corresponding odds, applies the OR to estimate the odds in the treated group, and converts that odds to the corresponding risk and calculates the risk difference, the inverse of which is the NNT. The cough indices were assumed to be normally distributed continuous variables so the mean difference in outcomes was estimated (weighted mean difference). If studies reported outcomes using different measurement scales, the standardised mean difference was estimated. Any heterogeneity between the study results was described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random-effects model was included whenever there were concerns about statistical heterogeneity. An a priori subgroup analysis was planned for children less than seven years of age. Sensitivity analyses were planned to assess the impact of the potentially important factors on the overall outcomes: a) study quality; b) study size; c) variation in the inclusion criteria; d) differences in the medications used in the intervention and comparison groups; e) differences in outcome measures; f ) analysis by 'intention to treat' but only including participants not lost to follow-up (available data analysis); g) analysis by 'treatment received' rather than 'intention to treat' and h) model used (RR versus OR) It was planned that publication bias be tested by use of a funnel plot.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies. The Airways Group register/search identified 2779 potentially relevant titles (see Appendix 2 for search history). After assessment of the abstracts, 13 papers were obtained for consideration for inclusion into the review. Two studies were included in the final review. The main reason studies were excluded was acute cough rather then chronic (five studies -see table of excluded studies). Other reasons included lack of randomisation and retrospective review articles. There were no studies which used oral antibiotic therapy for over seven days or intravenous therapy in children. The two studies included were single-centred studies and neither received support from commercial interests. Both studies were conducted in the setting of a paediatric outpatient clinic in Sweden and both recruited children with over 10 days of cough. Around 50% of patients had cough of greater than three weeks duration in one study (Darelid 1993 ) and the mean length of cough was three to four weeks in the other (Gottfarb 1994). The median age of participants in Darelid's study was not provided but 63% of the patients were aged one to three years (Darelid 1993) . Median age of children in Gottfarb's study was 2.6 years (Gottfarb 1994). The study populations appeared very similar. Although the quality of cough was not specifically outlined in either study, it is likely that the majority of children recruited had a moist cough as both studies included nasopharyngeal aspirates which grew a range of bacterial pathogens. Indeed, contact with trialists confirmed this as Dr Darelid estimated that >75% of participants in his trial had a moist cough (Darelid 1993 ). Both studies used short term antibiotic therapy (seven days). Both used paediatrician assessment of clinical recovery as primary outcome measure but the day of assessment was different (day eight (Darelid 1993 ) and day 12-14 (Gottfarb 1994)). The exclusion criteria of both studies included pneumonia, suspected B.pertussis infection and otitis media. The study by Darelid (Darelid 1993 ) also excluded children with allergy, asthma, cardiac disease and tonsillitis. This more comprehensive exclusion criteria provides a clearer definition of patients enrolled in the study and is a limitation of the other study. Neither study makes specific mention of the exclusion of patients with cystic fibrosis or bronchiectasis although it is assumed this is the case. Darelid et al's study (Darelid 1993 ) was an open randomised study comparing erythromycin and a no treatment control group. Gottfarb and colleagues (Gottfarb 1994) compared amoxicillin/clavulanic acid and placebo in a double-blinded randomised controlled study. Darelid (Darelid 1993 ) used a dosage regime of 50 mg/ kg/day which is equal to current recommended treatment dosage. The dosage in Gottfarb's study was lower (dosage 20 mg/kg/day) (Gottfarb 1994) then currently recommended doses (22.5 to 45 mg/kg/day) (Kemp 1997). Although different antibiotics were used in the studies, both would treat the respiratory pathogens found in the nasopharyngeal aspirates of these patients and organisms in bronchoalveolar lavage in other studies on chronic cough in children (Marchant JM 2003) . One study allowed the use of oral salbutamol mixture in both groups and this was recorded (Darelid 1993) . All the children in this study received oxymetazoline nose drops. Neither of these treatments should have influenced the outcome given they were available to both groups. No co-interventions were allowed in the second trial (Gottfarb 1994). Neither trial reported appropriately on compliance measures for patients although Darelid et al (Darelid 1993 ) reported 97% of patients completed the erythromycin medication. The trialists failed to state how this was assessed. Outcomes were assessed at day eight (Darelid 1993 ) and day 12 to 14 (Gottfarb 1994) respectively, so only short-term effects were described by the results. The primary outcome measure in both studies was paediatrician assessment of clinical outcome at followup. Patients were classified as cured or treatment failure. Both studies also reported parental assessment and used individual symp-tom scores as secondary outcome measures. Side effects and progression of disease requiring further antibiotic therapy was also documented. Darelid and colleagues (Darelid 1993 ) also recorded and documented the elimination of nasopharyngeal pathogens in the intervention and control groups. Gottfarb's (Gottfarb 1994) study excluded 15 children from the final analysis without indicating which treatment group they were initially allocated to. As contact with the authors was unsuccessful, we assumed that there were equal numbers of children in each group in the intention to treat analysis. Of the 15 children excluded 12 had laboratory confirmed Bordetella pertussis after randomisation which is a potential weakness of the study. Ideally the diagnosis of B.pertussis would have been made prior to randomisation and then these children would not have been eligible to enter the study.
Risk of bias in included studies
Darelid's study (Darelid 1993 ) had a Jadad score of two and that of Gottfarb (Gottfarb 1994) was three. The Jadad scores are consistent with the assessment of the individual components of the RCT quality. The study by Darelid (Darelid 1993 ) was high quality in terms of follow-up and reporting but poor quality for allocation concealment and blinding (open randomised study with 'no treatment' control group). The study by Gottfarb scored high in blinding measures only. Although both studies are randomised neither described the method of randomisation clearly. Although the study by Gottfarb and colleagues (Gottfarb 1994) was a double blind study it does not report how this was achieved. No mention of allocation concealment was made in either paper. The study by Darelid had only one withdrawal which is adequately described. The second study (Gottfarb 1994) had 15 patients who were withdrawn from the study. Although they mentioned the reasons for withdrawal, they failed to indicate which groups they have come from. A risk of bias assessment has been made for both studies (see 'Characteristics of included studies'). The agreement between the two reviewers (JM, AC) was good (weighted kappa score for Jadad scale was 1.0 and for quality assessment scores was 0.74).
Effects of interventions
The two studies included a total of 140 children. Sixteen patients were lost to follow-up or withdrew from the trial for other reasons, such as Bordetella pertussis infection. Both studies used short term antibiotic therapy of seven days. Primary outcome: a) Proportions of participants who were not cured or not substantially improved at follow-up (clinical failure). Data from both studies were combined for this outcome measure. The number of patients not cured at follow-up was 76 using intention to treat analysis. The control event rate was 64% (Darelid 1993 ) and 88% (Gottfarb 1994) in the two studies. Treatment with antibiotics reduced the proportion of children not cured at follow-up in both studies; the pooled OR effect estimate was 0.13 (95% CI 0.06 to 0.32). These studies suggest that one child will be cured for every three children treated (NNT = 3, 95%CI 2 to 4) (Figure 1 ). However the overall estimate of effect and degree of statistical heterogeneity were sensitive to the model used for metaanalysis (see sensitivity analysis). The subgroup data for children with prolonged moist cough for over three weeks were not available. All patients were aged seven years or less, so subgroup analysis could not be performed. The long-term effects of antibiotics were not assessed. Similar results were found for Streptococcus pneumoniae (treated elimination 100%; untreated 23%; P<0.0001). They also found a correlation with growth of Moraxella catarrhalis and persistent cough after the trial. In the untreated group, 80% of those with untreated Moraxella catarrhalis continued to cough versus 33% of those with no growth of this organism (P<0.01). d) Mean difference in cough indices (cough diary, cough frequency, cough scores) These measures could not be combined due to the differing nature of the indices. Darelid and colleagues (Darelid 1993 ) used a score which combined cough frequency, morning temperature and level of daily activity whereas Gottfarb and colleagues (Gottfarb 1994) looked at the number of coughing attacks in a 24 hour period. e) Proportions of participants with progression of the disease resulting in additional medical therapy (complications) Despite the differences in study design the proportion of patients with progression of disease can be combined using an 'intention to treatment' analysis of available data. Overall there were 125 children who contributed data on this outcome (excluding the 15 drop-outs in Gottfarb's study (Gottfarb 1994)). The overall control event rate for complications was 36% versus a treatment event rate of 5%. Progression of illness, as defined by requirement for further antibiotics in both papers, was significantly lower in the treatment group (pooled OR 0.10, 95%CI 0.03 to 0.34). The number needed to treat to avoid progression of disease was four (NNT = 4, 95%CI 3 to 5). f ) Proportions experiencing adverse effects of antibiotics e.g. diarrhoea, nausea, skin rash, allergic reactions (side effects) In Darelid's study, children in the erythromycin group had a reported side effect rate of 2% (Darelid 1993 ). The side effects noted were diarrhoea and vomiting. It can be argued that these results should not been pooled as one study (Darelid 1993 ) used a control group and therefore did not report any side effects for this population. The rate of side effects in the study comparing amoxicillin/ clavulanic acid and placebo was 12% for both treatment and control groups (Gottfarb 1994). Pooling the results, assuming that no one in the control (no treatment) group in Darelid's (Darelid 1993 ) had any adverse events, there was no significant difference between the groups; OR 1.38 (95%CI 0.31, 6.08). Sensitivity Analyses As there were only two studies in this review, reanalysis by study quality, size, differences in the medications used was not possible. When the analysis was performed using analysis by 'intention to treat' but only including participants not lost to follow-up (available data analysis) the primary outcome did not change; effect estimate 0.12 versus 0.13. Assessing the data by excluding those with proven Bordetella pertussis infection (Gottfarb 1994) did not change the OR from 0.13. Neither the analysis of available data only or of Gottfarb's study without the Bordetella pertussis patients (Gottfarb 1994) altered the number needed to treat. There was no difference when a random-effects model was used versus a fixedeffects model; OR for primary outcome 0.13 (fixed) versus 0.13 (random). Both the Chi 2 and I 2 statistical tools show low level of heterogeneity between the two studies, with I 2 =3.7% and Chi 2 = 1.04 for the primary outcome measure. In the primary outcome (clinical failure) the overall estimate of effect and degree of statistical heterogeneity were sensitive to the model used for meta-analysis (pooled RR 0.46, 95%CI 0.32 to 0.65 (fixed-effects model, I 2 92%); pooled RR 0.43, 95%CI 0.1 to 1.8 (random-effects model, I 2 92%). However the heterogeneity disappeared (using fixed model, I 2 0%) and pooled RR again favoured treatment 2.46 (95%CI 1.67, 3.64) when clinical success rather than clinical failure was used as the outcome measure. The 'proportions of participants with progression of the disease resulting in additional medical therapy' did not change substantially with the use of relative risks rather than odds ratios (from pooled OR of 0.10, 95%CI 0.03 to 0.34 (random-effects model) to pooled RR 0.15, 95%CI 0.05 to 0.49 (random-effects model)). In both models (OR or RR), there was no significant heterogeneity. Both results significantly favoured use of antibiotics to prevent progression of disease. Based on these results ORs (rather than RRs) were used throughout this review.
D I S C U S S I O N
This meta-analysis has suggested that antibiotics are effective treatment in children with a chronic moist cough, both in outcomes of 'clinical cure' and 'illness progression' (reduction in proportions of children subsequently requiring antibiotics). The data available indicate that in the population of children seven years or younger, with chronic cough three children will need to be treated to achieve one clinical cure. This supports the current American Pediatric URI Consensus Team statement that "antimicrobial treatment for prolonged cough (longer than 10 days) may be indicated occasionally" (Dowell 1998). These findings specific for prolonged cough differs from other reviews on antibiotics which showed that antibiotics have only minimal benefit (if any) in the treatment of acute bronchitis (Fahey 2004) and have no efficacy in treatment of the common cold (Arroll 2005).
In paediatrics, chronic cough is usually defined as cough duration of over three weeks. Ideally this review would include children with cough lasting over three weeks but there were no such studies. Both studies (Darelid 1993 ; Gottfarb 1994) used over 10 days of cough as the definition of prolonged cough. Certainly this would be classified as subacute cough in the available paediatric literature (Chang 2001). A percentage of the children with cough will cease spontaneous before 3 weeks (Hay 2002). Neither of the authors of the included studies were able to separate those with cough for 10-21 days versus those with over 21 days cough although both studies had a large percentage of children with cough over three weeks. The decision to include these studies which enrolled some children with shorter duration cough was made because although spontaneous resolution may occur in some patients it should occur equally in both treatment and placebo groups. Therefore is unlikely to alter the review outcome favourably but may limit the strength of it.
Neither study enrolled children with the particular cough characteristic of wet cough. A recent study has shown that the cough quality of wet vs dry cough can be validly used (Chang 2005). On correspondence with Darelid (Darelid 1993) , he reported that >75% of patients in his study had moist cough. Given the studies were carried out in the same geographical area and in similar patient group one could assume that the second study (Gottfarb 1994) had a similar proportion of children with moist cough. Since a chronic moist cough in this patient age group is more likely to be a bacterial bronchitis then any other cause (Marchant JM 2004) (and this should respond to antibiotic therapy) including children with dry cough would decrease any effect. This may explain the findings of this review that antibiotics appear to be beneficial for prolonged moist cough in children.
The pooled adverse events described in the two eligible studies showed no difference between the groups. The percentage of patients with side effects was low in both studies, being 2% in the study by Darelid for treatment group (Darelid 1993 ) and in Gottfarb's study (Gottfarb 1994) side effects were similar in both groups. In considering the trade-offs of antibiotic therapy one must remember that a small number of children will have adverse events as a result of the therapy (insufficient data to calculate number needed to harm). A further factor must be considered in the benefit versus harm debate and that is participants with progression of disease resulting in additional medical therapy (antibiotics). The control event rate was 36% (versus 5% in treated group) and the OR 0.10 significantly favouring treatment to decrease the incidence of complications for children with chronic wet cough.
Both studies (Darelid 1993 , Gottfarb 1994 ) used physician assessed 'clinical cure' as the outcome measure but these were undefined. Neither study assessed adequately differences in cough symptoms or used appropriate cough indices such as a cough diary or cough frequency. Therefore these measures have not been combined in meta-analysis. A previously validated cough diary (such as the verbal category descriptive (VCD) score for daytime and nocturnal cough (Chang 1998)) would have been helpful. It would have allowed patient data on cure, or otherwise, to be evaluated (rather than simply physician diagnosis of clinical cure). One excluded study (for an inadequate control group) (Yun 1983) did appropriately and accurately define 'clinical cure' as no cough present after 14 days of therapy. This study showed a significant benefit for antibiotics in keeping with our meta-analysis results with a significant difference between the antibiotic (treatment event rate for cure 46%) and expectorant/decongestant group (control cure event rate 14%) (p<0.001) but was unable to be included in the meta-analysis as it did not meet inclusion criteria.
Although neither study assessed specifically differences in sputum, bronchoalveolar lavage or blood indices of inflammation and infection the paper by Darelid (Darelid 1993 ) looked at the organisms grown on nasopharyngeal aspirate and the clearance of these post-treatment. It showed a significant elimination of Moraxella catarrhalis from the nasopharynx of treated patients. The presence of this organism in bronchoalveolar lavage of children with chronic bacterial bronchitis who presented with chronic cough has been recently found, along with predominantly Streptococcus pneumoniae and Haemophilus influenzae (Marchant JM 2004). The organisms found on bronchoalveolar lavage in this patient population are vital when considering appropriate antibiotic therapy. The two studies have chosen different antibiotics, erythromycin (dosage of 50 mg/kg/day) (Darelid 1993 ) and amoxicillin/clavulanic acid (dosage 20 mg/kg/day) (Gottfarb 1994). Darelid's study (Darelid 1993 ) trialed erythromycin, a macrolide antibiotic, which has traditionally covered the common pathogens found in the lower respiratory tract such as Streptococcus pneumoniae and Haemophilus influenzae (as well as the atypical pathogens such as Mycoplasma species) (Alvarez-Elcoro 1999). Increasing emergence of macrolide resistance to the common pathogens may limit their usefulness in the future as illustrated by a recent study which found 13.7% of Streptococcus pneumoniae in school-aged children were resistant to erythromycin (Gazi 2004). In contrast Gottfarb used Augmentin (amoxicillin/clavulanic acid) an antibiotic with broad coverage of the organisms likely to be found on bronchoalveolar lavage in children with chronic wet cough, namely Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (Marchant JM 2004) . In the study by Gazi (Gazi 2004) only 1.2% of Haemophilus influenzae were resistant to amoxicillin/clavulanic acid and none of the Moraxella catarrhalis or Streptococcus pneumoniae. Gottfarb has chosen a very low dosage schedule (20 mg/kg/day) compared with standard practice (45 mg/kg/day) which may limit the efficacy of the drug and so rate of clinical cure in the trial (Kemp 1997). The ideal RCT would trial appropriate antibiotic therapy used at an appropriate dosage to treat the organisms predominantly found on bronchoalveolar lavage in children.
Limitations of review
This systematic review is limited to two small studies of poor quality with limited availability of data for analysis. Some assumptions about the data were made for both studies (cough quality and equal dropouts in intervention and control groups). Neither of the studies scored highly on the Jadad quality scale or the individual assessment of each important quality component. The review is also limited by lack of inclusion of validated objective measures of cough, such as the verbal category descriptive cough diary (Chang 1998). The lack of data on quality of cough allows the possibility of greater clinical heterogeneity of participants then one would anticipate. The failure to state exclusion of children with cystic fibrosis, bronchiectasis and other underlying lung disease, although implied, is another flaw of both studies which needs to be addressed in subsequent RCTs. Inclusion of children with these disease states may influence the results of this meta-analysis.
A U T H O R S ' C O N C L U S I O N S Implications for practice
When considering implications for practice of this review one must remember the data is based on two small studies with methodological flaws. Clearly further high-quality studies are needed before this evidence can be accepted as conclusive. Acknowledging this the available evidence suggests that antibiotics are efficacious in young children, aged seven years or less, with prolonged wet cough with three or four patients cured for every 10 treated. The use of antibiotics in children with prolonged wet cough is also associated with a reduction in the progression of illness whereby children on antibiotics are less likely to require further antibiotics for treatment of complications. One must remember antibiotics are not without side effects when considering this treatment option. The conclusions of this review are applicable only to children with persistent wet cough which must be differentiated from acute cough where the role of antibiotics is clearly very different and has been addressed in other reviews.
Implications for research
Well designed RCTs which use appropriate randomisation, double-blinding and allocation concealment are required to assess the role of antibiotics in chronic moist cough in children. The trials should include children with cough of > 3 weeks to assess only those with chronic cough, and so avoid the natural resolution that can occur in the first three weeks. The addition of cough quality (wet cough only) to the inclusion criteria for participants will decrease the clinical heterogeneity within the subjects. It is important that future RCTs exclude children with bronchiectasis, cystic fibrosis and underlying chronic lung disease and cough related to B.pertussis or Mycoplasma pneumoniae. Children with specific cough such as wheeze on auscultation should also be excluded as these may indicate other underlying pathology and again broadens the heterogeneity of the trial participants (possibly decreasing the efficacy of the antibiotic treatment). The design of future RCTs should include objective measures of cough outcomes such as cough frequency or validated symptomatic measures such as cough diary or visual analogue scale as assessed by the child (if age permits) or the parent/carers. A clear and appropriate definition of clinical cure should be included in the trial design. Secondary measures such as differences in sputum, bronchoalveolar lavage or blood indices of inflammation or infection will also strengthen future trial outcomes. Future RCTs should incorporate sufficient longitudinal follow-up of these patients to assess the longevity of clinical cure in these patients.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Darelid 1993
Methods
Open randomised study comparing erythromycin and no treatment (as control group).
At baseline patients had a history and clinical examination performed. A nasopharyngeal swab was obtained at baseline and again 18-36 hours after last antibiotic dose. A repeat doctors examination was performed on Day 8 Randomisation was open and done by a computer-generated table. No other information given about randomisation. Allocation concealment was not done (grade C). Not blinded due to open design of study (quality assessment grade D). Compliance monitoring not described Dropouts: n=1 (1.1% of patients randomised) from treatment group from adverse effects of antibiotics. No further description given and was not included in analysis as treatment failures. Quality assessment of reporting of participants and follow-up of patients therefore were of a high quality (A) Participants 88 children with cough >10 days duration were included. The number of participants with cough > 3 weeks duration was 50%. Approximately 75% of the participants had moist cough. Erthromycin group: n=41 Control group n=47 . There were no significant differences in any patient characteristics between the 2 groups Inclusion criteria: Children aged 0.5 -6 years attending one of 3 paediatric outpatient clinics with greater than 10 days of cough Exclusion criteria: Children with allergy, asthma, cardiac disease, otitis media, tonsillitis, pneumonia or clinically suspected pertussis Interventions Treatment group received erythromycin ethylsuccinate suspension 50mg/kg/day in 2 divided doses for 7 days verus 'no treatment' control group. All children received nose drops (oxymetazoline chloride). Salbutamol mixture (0.1mg/kg/day) was allowed in both groups and was registered 
Gottfarb 1994
Methods Randomised double blind study comparing Amoxycillin/clavulanic acid vs placebo. At baseline clinical data was obtained and participants underwent nasopharyngeal aspirate and blood tests for B.pertussis and Mycoplasma pneumoniae. A cough scoring system which combined number of coughing attacks per 24 hours, coughing attacks associated with vomiting and wheeze or crackles on auscultation was obtained. At 2 weeks participants were followed-up with repeat blood tests, nasopharyngeal aspirates and doctor assessment of clinical outcome. Parental assessment of treatment efficacy was also recorded. Number of coughing attacks per 24 hours was recorded for each day of treatment Randomisation method was not described. Allocation method was not described. Compliance monitoring was not described. Although a double-blinded study there was no mention of how this was achieved in the paper Dropouts n=15 (26.3% of those recruited). 12 with pertussis, 2 failed to return to followup visit, 1 refused medication. These were not further described and not included as treatment failures in the paper Participants 52 children with cough >10 days duration were included. The mean duration of cough was 3-4 weeks. Number with moist cough was not reported. Median age of groups: Amoxycillin/clavulanic acid 2.7 years; Placebo 2.6 years (Numbers in each group not described).There was no significant differences in any patient characteristics between the two groups Inclusion criteria: Children aged 0.6-7 years with > 10 days of cough and > 7 points on cough score system Exclusion criteria: Children with any signs of pneumonia, acute otitis media or clinical suspicion of Bordetella pertussis infection Interventions Treatment group received amoxycillin/clavulanic acid 20mg/kg/day for 7 days verus placebo group. The children were not given any antitussive medication. Yun 1983 RCT of antibiotics for sinusitis in children presenting with chronic cough. Excluded because no placebo or "no treatment" control group. The non-antibiotic group was given expectorants and decongestants which is not an appropriate control/placebo group. There was also no information given on nature of cough, moist or dry. It did however precisely defined "clinical cure" as no cough on day 14 of treatment. The results did suggest benefit with antibiotics in keeping with our results with the difference between the antibiotic( treatment event rate for cure 46%) and expectorant/decongestant group ( control cure rate 14%) which was statistically significant (p<0.001)
Characteristics of ongoing studies [ordered by study ID]
Marchant
Trial name or title Randomised controlled double-blinded trial of antibiotics in patients with chronic moist cough
Methods
Participants
Children aged 6 months -14 years with chronic (>3 week duration) moist cough. Exclusion criteria: Clinical or HRCT-proven bronchiectasis, gross neurodevelopmental delay, cystic fibrosis, known chronic disease such as interstitial lung disease or cardiac disease. Also children who have had antibiotic therapy in the preceding 2 weeks or who are allergic to penicillin will be excluded Interventions Randomisation stratified by age <6 years or > 6 years. Allocated blindly to Augmentin Duo Suspension 400mg/5ml or placebo at dose 22.5mg/kg twice daily for 14 days. Enrolled children will complete cough diary cards for 5 days pre intervention and total of 4 weeks after intervention. Bronchoscopy and lavage will take place on day 0 in a number of children Outcomes Primary Outcome: Assessment of cough scores -pre treatment, immediately prior to treatment and at conclusion of treatment. Bronchoalveolar lavage results in responders and non-responders will also be compared including cytology, microbiology and inflammatory markers 
C O N T R I B U T I O N S O F A U T H O R S
For the protocol: Protocol was written by JM and AC, based on previous protocols on cough in children. PM and JG reviewed protocol. For the review: JM: selection of articles from search, data extraction, data analysis and writing of review. AC: review of articles for inclusion, data extraction, double data entry, data analysis, writing of review. JG: selection of articles from search. PM: reviewed written review.
D E C L A R A T I O N S O F I N T E R E S T
Two of the authors (JM and AC) are investigators in an RCT of antibiotics for prolonged moist cough in children. This trial is currently in progress.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children's Hospital Foundation, Brisbane, Australia.
External sources
• Australian Cochrane Airways Group Scholarship 2004, Australia.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
October 2004: During the review process the selection criteria was changed from RCTs comparing antibiotics to placebo medication to also include studies comparing antibiotics with a 'no treatment' control group. This was done because there were an insufficient number of placebo-controlled trials to be sure that the information obtained from unblinded studies would not be clinically useful. The inclusion criteria were changed to allow studies of children who had prolonged moist cough for >10 days. We planned to assess the impact of antibiotics on children with prolonged moist cough >3 weeks (our preferred definition of chronic cough) as an a priori subgroup analysis. We also decided to include studies that were not exclusively limited to children with "moist sounding" cough if subgroup data were not available and >50% of children had a moist cough or other clinical features consistent with diagnosis (e.g. sputum production, excess secretions etc). The review uses a summary weighted odds ratio rather than relative risk as was stated in the protocol. This decision was made as it appeared the most clinically relevant analysis method particularly when converted to number needed to treat.
